Charting a path forward for patients living with TN.
Trigeminal Neuralgia
KRIYA.748 is an investigational gene therapy designed to quiet overactive pain signaling in the trigeminal nerve, aiming to reduce the frequency and severity of pain associated with trigeminal neuralgia.
Trigeminal Neuralgia (TN) is an extremely painful disease, causing debilitating, recurrent, electric shock like facial pain in many patients. Triggered by gentle, everyday movements, it can severely impair a person’s ability to work and live day-to-day. TN has been described as the “suicide disease,” given the severity and unpredictable nature of the pain.
KRIYA.748
How it works
Trigeminal Neuralgia causes debilitating, frequent and sudden facial pain episodes due to the trigeminal nerve firing abnormally. KRIYA.748 is designed to deliver an engineered ion channel to the nerve following a single administration. When modulated by oral varenicline, the channel dampens the overactive signaling that drives pain. Because the channel is engineered to be active only while varenicline is taken, the effect is designed to be controllable and reversible.
Loading…
Failed to load vial.
Specifications
| Indication | Trigeminal neuralgia (TN) |
|---|---|
| Modality | AAV-based gene therapy |
| Mechanism | Reversible neuronal inhibition |
| Payload | Engineered ion channel |
| Selective control | Oral varenicline |
| Delivery | Percutaneous injection, outpatient |
| Dosing frequency | Single administration |
| Potential patient impact | ~400,000 US and EU |
| Stage | Phase 1/2 |
Disclaimer
Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.
